TITLE:
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.

CONDITION:
Hepatitis B

INTERVENTION:
clevudine (drug)

SUMMARY:

      The purpose of the study is to evaluate the safety and effectiveness of 12 weeks of
      treatment with clevudine, at one of three doses, in patients chronically infected with
      hepatitis B virus.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 60 Years
Criteria:

        Inclusion Criteria:

          -  HBV DNA positive with DNA levels at screening greater than or equal to 3,000,000
             copies/mL.

          -  Documented to be HBsAg positive for > 6 months OR HBsAg positive and IgM anti-HBc
             negative and anti-HBs negative. Patients may be HBeAg positive, and anti-HBe negative
             OR HBeAg negative (pre-core mutant) and anti-HBe positive.

          -  HBeAg positive and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe
             positive with positive HBsAg for the previous 6 months

          -  AST and ALT levels which are less than or equal to 10 times the upper limit of
             normal.

          -  Bilirubin levels less than or equal to 1.5 x ULN or bilirubin levels > 1.5 x ULN with
             diagnosis of Gilberts disease and conjugated bilirubin within normal limits.

        Exclusion Criteria:

          -  Currently receiving antiviral, immunomodulatory or corticosteroid therapy

          -  Previous treatment with lamivudine, lobucavir, adefovir, famciclovir, or any other
             investigational nucleoside for HBV infection

          -  Previous treatment with interferon must have ended at least 6 months prior to
             screening visit

          -  History of ascites, variceal hemorrhage or hepatic encephalopathy

          -  Co-infection with HCV or HIV

          -  Evidence of cirrhosis or hepatocellular carcinoma (alpha fetoprotein)
      
